Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain

Breast Cancer Research

Volumn 14, Issue 4, 2012, Pages

  Duchnowska, Renata ^a   Dziadziuszko, Rafał ^b   Trojanowski, Tomasz ^c   Mandat, Tomasz ^d   Och, Waldemar ^e   Czartoryska Arłukowicz, Bogumiła ^f   Radecka, Barbara ^g   Olszewski, Wojciech ^d   Szubstarski, Franciszek ^h   Kozłowski, Wojciech ^a   Jarosz, Bozena ^c   Rogowski, Wojciech ⁱ   Kowalczyk, Anna ^b   Limon, Janusz ^b   Biernat, Wojciech ^b   Jassem, Jacek ^b   Matyskiel, Anita ^b   Szostakiewicz, Barbara ^b   Sosinska Mielcarek, Katarzyna ^b   Szutowicz Zielinska, Ewa ^b   Grala, Bartlomiej ^a   Wiraszka, Robert ^j   Kalinka Warzocha, Ewa ^k   Staszkiewicz, Rafal ^l   Szóstak, Blazej ^l   Chudzik, Malgorzata ^d   more..

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^d INSTITUTE OF ONCOLOGY   (Poland)

^e Voivodal Specialistic Hospital   (Poland)

^f Oncology Center of Bialystok   (Poland)

^g Opole Oncology Center   (Poland)

^h Lublin Oncology Center   (Poland)

ⁱ Warmia and Masuria Oncology Center   (Poland)

^j Regional Specialist Hospital   (Poland)

^k Regional Oncological Centre   (Poland)

^l Ministry of Interior Affairs Hospital   (Poland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; LAPATINIB; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB; ESTROGEN RECEPTOR;

ARTICLE; BRAIN METASTASIS; BRAIN SURGERY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROTEIN EXPRESSION; SCORING SYSTEM; ADULT; AGED; BRAIN TUMOR; BREAST NEOPLASMS; CANCER GRADING; CLINICAL TRIAL; FOLLOW UP; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SECONDARY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOPLASM GRADING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84864913939     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3244     Document Type: Article

References (44)

1. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004, 22:3608-3617. 10.1200/JCO.2004.01.175, 15337811.
2. Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, Crivellari D, Fey MF, Murray E, Pagani O, Simoncini E, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A. International Breast Cancer Study Group (IBCSG): identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006, 17:935-944. 10.1093/annonc/mdl064, 16603601.
3. Harrell JC, Prat A, Parker JS, Fan C, He X, Carey L, Anders C, Ewend M, Perou CM. Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res Treat 2012, 132:523-535. 10.1007/s10549-011-1619-7, 3303043, 21671017.
4. Gaedcke J, Traub F, Milde S, Wilkens L, Stan A, Ostertag H, Christgen M, von Wasielewski R, Kreipe HH. Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer. Modern Pathol 2007, 20:864-870.
5. Crivellari D, Pagani O, Veronesi A, Lombardi D, Nolè F, Thürlimann B, Hess D, Borner M, Bauer J, Martinelli G, Graffeo R, Sessa C, Goldhirsch A, International Breast Cancer Study Group High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol 2001, 12:353-356. 10.1023/A:1011132609055, 11332148, International Breast Cancer Study Group.
6. Ryberg M, Nielsen D, Osterlind K, Andersen PK, Skovsgaard T, Dombernowsky P. Predictors of central nervous system metastasis in patients with metastatic breast cancer: a competing risk analysis of 579 patients treated with epirubicin-based chemotherapy. Breast Cancer Res Treat 2005, 91:217-225. 10.1007/s10549-005-0323-x, 15952055.
7. Duchnowska R, Szczylik C. Central nervous system metastases in breast cancer patients administered trastuzumab. Cancer Treat Rev 2005, 31:312-318. 10.1016/j.ctrv.2005.04.008, 15979804.
8. Guarneri V, Giovannelli S, Ficarra G, Bettelli S, Maiorana A, Piacentini F, Barbieri E, Dieci MV, D'Amico R, Jovic G, Conte P. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist 2008, 13:838-844. 10.1634/theoncologist.2008-0048, 18650259.
9. Hoefnagel LD, van de Vijver MJ, van Slooten HJ, Wesseling P, Wesseling J, Westenend PJ, Bart J, Seldenrijk CA, Nagtegaal ID, Oudejans J, van der Valk P, van der Groep P, de Vries EG, van der Wall E, van Diest PJ. Receptor conversion in distant breast cancer metastases. Breast Cancer Res 2010, 12:R75. 10.1186/bcr2645, 3096964, 20863372.
10. Curigliano G, Bagnardi V, Viale G, Fumagalli L, Rotmensz N, Aurilio G, Locatelli M, Pruneri G, Giudici S, Bellomi M, Della Vigna P, Monfardini L, Orsi F, Nolè F, Munzone E, Goldhirsch A. Should liver metastases of breast cancer be biopsied to improve treatment choice?. Ann Oncol 2011, 22:2227-2233. 10.1093/annonc/mdq751, 21343379.
11. Gong Y, Han EY, Guo M, Pusztai L, Sneige L. Stability of estrogen receptor status in breast carcinoma: a comparison between primary and metastatic tumors with regard to disease course and intervening systemic therapy. Cancer 2011, 117:705-713. 10.1002/cncr.25506, 20939012.
12. Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault RL, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009, 20:1953-1958. 10.1093/annonc/mdp263, 2791352, 19596702.
13. Karlsson E, Lindstrom LS, Wilking U, Skoog L, Johansson U, Bergh. Discordance in hormone receptor status in breast cancer during tumor progression. J Clin Oncol 2010, 28(suppl):s116.
14. Houssami N, Macaskill P, Balleine RL, Bilous M, Pegram MD. HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? insights through meta-analysis. Breast Cancer Res Treat 2011, 129:659-674. 10.1007/s10549-011-1632-x, 21698410.
15. Xiao C, Gong Y, Han EY, Gonzalez-Angulo AM, Sneige N. Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment. Ann Oncol 2011, 22:1547-1553. 10.1093/annonc/mdq623, 21239403.
16. Chang HJ, Han SW, Oh DY, Im SA, Jeon YK, Park IA, Han W, Noh DY, Bang YJ, Kim TY. Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab. Jpn J Clin Oncol 2011, 41:593-599. 10.1093/jjco/hyr020, 21406492.
17. Grupka NL, Lear-Kaul KC, Kleinschmidt-DeMasters BK, Singh M. Epidermal growth factor receptor status in breast cancer metastases to the central nervous system: comparison with HER-2/neu status. Arch Pathol Lab Med 2004, 128:974-979.
18. Yonemori K, Tsuta KC, Shimizu C, Hatanaka Y, Hashizume K, Ono M, Nakanishi Y, Hasegawa T, Miyakita Y, Narita Y, Shibui S, Fujiwara Y. Immunohistochemical profiles of brain metastases from breast cancer. J Neurooncol 2008, 90:223-228. 10.1007/s11060-008-9654-x, 18648908.
19. Shao M, Liu J, Vong JS, Shao MM, Niu Y, Germin B, Tang P, Chan AW, Lui PC, Law BK, Tan PH, Tse GM. A subset of breast cancer predisposes to brain metastasis. Med Mol Morphol 2011, 44:15-20. 10.1007/s00795-010-0495-2, 21424932.
20. Fuchs IB, Loebbecke M, Buhler H, Stoltenburg-Didinger G, Heine B, Lichtenegger W, Schaller G. HER2 in brain metastases: issues of concordance, survival, and treatment. J Clin Oncol 2002, 20:4130-4133. 10.1200/JCO.2002.99.148, 12351618.
21. Brogi E, Murphy CG, Johnson ML, Conlin AK, Hsu M, Patil S, Akram M, Nehhozina T, Jhaveri KL, Hudis CA, Seidman AD. Breast carcinoma with brain metastases: clinical analysis and immunoprofile on tissue microarrays. Ann Oncol 2011, 22:2597-2603. 10.1093/annonc/mdr022, 21427063.
22. Lear-Kaul KC, Yoon HR, Kleinschmidt-DeMasters BK, McGavran L, Singh M. Her-2/neu status in breast cancer metastases to the central nervous system. Arch Pathol Lab Med 2003, 127:1451-1457.
23. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998, 11:155-168.
24. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28:2784-2795. 10.1200/JCO.2009.25.6529, 2881855, 20404251.
25. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977, 33:159-174. 10.2307/2529310, 843571.
26. Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, Oldfield M, Dranitsaris G, Tomlinson G, Laupacis A, Tannock IF, Clemons M. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012, 30:587-592. 10.1200/JCO.2010.33.5232, 22124102.
27. Amir E, Clemons M, Purdie CA, Miller N, Quinlan P, Geddie W, Coleman RE, Freedman OC, Jordan LB, Thompson AM. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev 2012, 38:708-714. 10.1016/j.ctrv.2011.11.006, 22178456.
28. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, Harris CC, McLellan MD, Fulton RS, Fulton LL, Abbott RM, Hoog J, Dooling DJ, Koboldt DC, Schmidt H, Kalicki J, Zhang Q, Chen L, Lin L, Wendl MC, McMichael JF, Magrini VJ, Cook L, McGrath SD, Vickery TL, Appelbaum E, Deschryver K, Davies S, Guintoli T, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010, 464:999-1005. 10.1038/nature08989, 2872544, 20393555.
29. Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G, Clemons MJ. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?. Ann Oncol 2009, 20:1499-1504. 10.1093/annonc/mdp028, 2731014, 19299408.
30. Kuukajarvi T, Karhu R, Tanner M, Kähkönen M, Schäffer A, Nupponen N, Pennanen S, Kallioniemi A, Kallioniemi OP, Isola J. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res 1997, 57:1597-1604.
31. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS, Polyak K. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007, 11:259-273. 10.1016/j.ccr.2007.01.013, 17349583.
32. Hoefnagel LD, Moelans CB, Meijer SL, van Slooten HJ, Wesseling P, Wesseling J, Westenend PJ, Bart J, Seldenrijk CA, Nagtegaal ID, Oudejans J, van der Valk P, van Gils CH, van der Wall E, van Diest PJ. Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases. Cancer 2012, Mar 13. doi: 10.1002/cncr.27518.
33. Niikura N, Liu J, Hayashi N, Mittendorf EA, Gong Y, Palla SL, Tokuda Y, Gonzalez-Angulo AM, Hortobagyi GN, Ueno NT. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 2012, 30:593-599. 10.1200/JCO.2010.33.8889, 22124109.
34. Chen G, Davies MA. Emerging insights into the molecular biology of brain metastases. Biochem Pharmacol 2012, 83:305-314. 10.1016/j.bcp.2011.09.012, 21946085.
35. Zhang C, Yu D. Microenvironment determinants of brain metastasis. Cell Biosci 2011, 1:8. 10.1186/2045-3701-1-8, 3125212, 21711688.
36. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA, Martens JW. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008, 68:3108-3114. 10.1158/0008-5472.CAN-07-5644, 18451135.
37. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010, 28:3271-3277. 10.1200/JCO.2009.25.9820, 20498394.
38. Pusztai L, Viale G, Kelly CM, Hudis CA. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist 2010, 15:1164-1168. 10.1634/theoncologist.2010-0059, 3227913, 21041379.
39. Weigelt B, Glass AM, Wessels LF, Witteveen AT, Peterse JL, van't Veer LJ. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci USA 2003, 100:15901-15905. 10.1073/pnas.2634067100, 307665, 14665696.
40. Duchnowska R, Jassem J, Shen C, Thorat M, Li L, Morimiya A, Zhao Q, Biernat W, Mandat T, Staszkiewicz R, Och W, Szostak W, Gugala K, Trojanowski T, Czartoryska-Arlukowicz B, Szczylik C, Nakshatri H, Steeg P, Sledge G, Badve S. Molecular characteristics of matched brain metastasis (BM) versus the primary breast cancer (PBC). Cancer Res 2009, 69(suppl 2):s164.
41. Chung GG, Zerkowski MP, Ghosh S, Camp RL, Rimm DL. Quantitative analysis of estrogen receptor heterogeneity in breast cancer. Lab Invest 2007, 87:662-669. 10.1038/labinvest.3700543, 17334408.
42. Cardoso F, Fallowfield L, Costa A, Castiglione M, Senkus E, ESMO Guidelines Working Group Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011, 22(suppl 6):vi25-vi30. ESMO Guidelines Working Group.
43. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (abridged version). Arch Pathol Lab Med 2010, 134:e48-72.
44. Bachelot TD, Romieu G, Campone M, Dieras V, Cropet C, Roche HH, Jimenez M, Le Rhun E, Pierga J, Gonçalves A, Leheurteur M, Domont J, Gutierrez M, Cure H, Ferrero J, Labbe C. LANDSCAPE: a FNCLCC phase II study with lapatinib and capecitabine in patients with brain metastases from HER2-positive metastatic breast cancer before whole brain radiotherapy. J Clin Oncol 2011, 29(suppl):s47.